Exin Therapeutics
Exin Therapeutics is a YC Winter 2025 (W25) company. Based in San Francisco, CA, USA. Team of 3.
About Exin Therapeutics
Summary
Exin Therapeutics builds an AI-driven drug discovery platform for neurotherapeutics, targeting diseases defined by dysfunctional neural activity. The platform uses multimodal AI models trained on high-density in-house mouse data to predict how drug candidates affect multiple neurological disorders simultaneously, starting with epilepsies linked to autism and Parkinson's disease. It replaces conventional trial-and-error screening by directing target discovery across disorders and therapeutic modalities from a single platform.
From the Y Combinator listing
AI drug discovery platform for neurotherapeutics
We use AI and high-throughput mouse studies to discover therapeutics that modify neural activity in the brain. The initial focus is on epilepsies associated with autism and Parkinson’s disease with the potential to expand to any neurological disorder underlined by a dysfunction in neural activity. Our R&D is guided by AI models trained on high-density multimodal mouse data generated in-house. We are 3 Oxford-trained neuroscientists supported by an experienced SAB from Harvard, Science Corp (ex-Neuralink), EPFL, Meta, and UCL. In 1.5 months since landing in SF, we went from nothing to (1) opening and operating an animal lab in South SF, (2) obtaining a proof-of-concept in mice, (3) building a multimodal AI model that directs our screening approach and (4) submitting two provisional patents; all while utilizing less than 50% of our YC funding.
Facts
- Healthcare / Healthcare -> Therapeutics
- San Francisco, CA, USA
- 3
- Active
- Early
Founders (3)
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works